Efficacy of Secukinumab in Moderate-Severe Psoriasis with Reduced Treatment Regimen

**Autores:**
M.D.V. Sánchez Matamoros Piazza1, C. Puivecino Moreno1, C. Cuadros Martínez1, A. Varas Pérez1, A. Alcalá Soto1.

1Hospital Universitario Jerez de la Frontera, Pharmacy Service, Jerez de la Frontera- Cádiz, Spain.

**Background:**
Secukinumab, anti-IL-17 drug has proved to be effective in the treatment of psoriasis being its recommended dose according to the 300 mg data sheet at week 0, 1, 2, 3 and 4 and then monthly, during the phase of maintenance.

**Purpose:**
To evaluate the efficacy of a reduced monthly dose of 150 mg in patients with moderate-severe psoriasis.

**Materials and Methods:**
A retrospective observational study that included patients treated with secukinumab until March 2019. The variables recorded were: sex, previous biological treatments, PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life Quality Index) initial and late, and also increases in dosage. Efficacy was assessed by the % reduction in PASI and according to DLQI score. The data were obtained from the dispensing registry of outpatients and the medical history.

**Results:**
- 44 pacientes
- The initial average value of DLQI = 8.43 (DS = 5.81)
- The initial average value of PASI = 6.36 (DS = 3.43)

**Conclusions:**
The reduced Secukinumab regimen of 150mg monthly both in patients who use it as a first line of biological treatment or after failure with previous treatments, has proven to be an effective EEAHP 2020 Gothenburg, Sweden